Upping the ante on antibodies

被引：77

作者：

Baker, M

机构：

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 09期

关键词：

D O I：

10.1038/nbt0905-1065

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The current generation of antibodies has done more than make a few companies rich. It has laid the groundwork for ambitious companies to move to maturity. © 2005 Nature Publishing Group.

引用

收藏

页码：1065 / 1072

页数：8

相关论文

共 4 条

[1] EVANS D, 2005, MONOCLONAL ANTIBODIE
[2] Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody
Lu, D
Zhang, HF
Ludwig, D
Persaud, A
Jimenez, X
Burtrum, D
Balderes, P
Liu, ML
Bohlen, P
Witte, L
Zhu, ZP
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (04) : 2856 - 2865
[3] Next-generation monoclonals less profitable than trailblazers?
Mitchell, P
[J]. NATURE BIOTECHNOLOGY, 2005, 23 (08) : 906 - 906
[4] Antibody engineering for therapeutics
Presta, L
[J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 2003, 13 (04) : 519 - 525